ReviewWorld journal of gastroenterology2018
Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases.
Review in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease.The Cochrane database of systematic reviews · 2020Pooled it
- Pooled it
- Latent tuberculosis screening for inflammatory bowel disease in tuberculosis endemic region remains porous and suboptimal: A multicentre study.World journal of gastroenterology · 2026Article
- The Importance of Post-Inflammatory Polyps (PIPs) in Colorectal Cancer Surveillance in Inflammatory Bowel Diseases.Journal of clinical medicine · 2025Review
- Controversies in the management of anti-TNF therapy in patients with Crohn's disease: a Delphi consensus.BMJ open gastroenterology · 2024Review
- A potential therapeutic approach for ulcerative colitis: targeted regulation of mitochondrial dynamics and mitophagy through phytochemicals.Frontiers in immunology · 2024Review
- Mucosal Genes Expression in Inflammatory Bowel Disease Patients: New Insights.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All.Journal of Crohn's & colitis · 2022Article
- Increased risk of colorectal neoplasia in inflammatory bowel disease patients with post-inflammatory polyps: A systematic review and meta-analysis.World journal of gastrointestinal oncology · 2022Article
- Epidemiology and Characteristics of Chronic Pancreatitis-Do the East and West Meet?Gastro hep advances · 2022Review
- Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis.RMD open · 2021Article
- Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease.Journal of clinical medicine · 2021Review
- Precision medicine in inflammatory bowel disease: concept, progress and challenges.F1000Research · 2020Review
- Perturbed Mitochondrial Dynamics Is a Novel Feature of Colitis That Can Be Targeted to Lessen Disease.Cellular and molecular gastroenterology and hepatology · 2020Article
- Pharmacokinetic Profiling and Simultaneous Determination of Thiopurine Immunosuppressants and Folic Acid by Chromatographic Methods.Molecules (Basel, Switzerland) · 2019Article
- Mucosal gene expression changes induced by anti-TNF treatment in inflammatory bowel disease patients.Drug development research · 2019Article
- Novel Non-biologic Targets for Inflammatory Bowel Disease.Current gastroenterology reports · 2019Review
- Anti-inflammatory effects of apocynin on dextran sulfate sodium-induced mouse colitis model.PloS one · 2019Article
- Impact of Modern Drug Therapy on Surgery: Crohn's Disease.Visceral medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past decade has brought substantial advances in the management of inflammatory bowel diseases (IBD). The introduction of tumor necrosis factor (TNF) antagonists, evidence for the value of combination therapy, the recognition of targeting lymphocyte trafficking and activation as a viable treatment, and the need for early treatment of high-risk patients are all fundamental concepts for current modern IBD treatment algorithms. In this article, authors review the existing data on approved biologicals and small molecules as well as provide insight on the current positioning of approved therapies. Patient stratification for the selection of specific therapies, therapeutic targets and patient monitoring will be discussed as well. The therapeutic armamentarium for IBD is expanding as novel and more targeted therapies become available. In the absence of comparative trials, positioning these agents is becoming difficult. Emerging concepts for the future will include an emphasis on the development of algorithms which will facilitate a greater understanding of the positioning of novel biological drugs and small molecules in order to best tailor therapy to the patient. In the interim, anti-TNF therapy remains an important component of IBD therapy with the most real-life evidence and should be considered as first-line therapy in patients with complicated Crohn's disease and in acute-severe ulcerative colitis. The safety and efficacy of these 'older' anti-TNF therapies can be optimized by adhering to therapeutic algorithms which combine clinical and objective markers of disease severity and response to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.